ArticleThe Journal of international medical research2021
Lymphocyte cytosolic protein 2 is a novel prognostic marker in lung adenocarcinoma.
Article in The Journal of international medical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Identification of novel ceRNA networks associated with system hemostasis and their prognostic implication in lung squamous cell carcinoma.Journal of thrombosis and thrombolysis · 2026Article
- Integrated analysis of single-cell and bulk-RNA sequencing for the cellular senescence in prognosis of lung adenocarcinoma.Scientific reports · 2025Article
- Main Genes Linked to the Immune Microenvironment in High-Grade Serous Ovarian Cancer.Advanced biomedical research · 2025Article
- Title: Bioinformatic Identification of Genes Involved in Diabetic Nephropathy Fibrosis and their Clinical Relevance.Biochemical genetics · 2023Article
- Identification of useful biomolecular markers in kidney renal clear cell carcinoma: an in silico and in vitro analysis-based study.American journal of translational research · 2023Article
- [MiR-4772 modulates tumor immune microenvironment by regulating immune- related genes in ovarian cancer].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Article
- Apprising Diagnostic and Prognostic Biomarkers in Cutaneous Melanoma-Persistent Updating.Journal of personalized medicine · 2022Review
- Identification of hub genes and transcription factors in patients with rheumatoid arthritis complicated with atherosclerosis.Scientific reports · 2022Article
- ABI3BP is a prognosis biomarker related with clinicopathological features and immunity infiltration of lung tumor.Frontiers in genetics · 2022Article
- Construction of Prognostic Risk Model for Small Cell Lung Cancer Based on Immune-Related Genes.Computational and mathematical methods in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLymphocyte cytosolic protein 2 (LCP2) is often ectopically expressed in various human tumors. However, the clinical significance and role of LCP2 in lung adenocarcinoma (LUAD) remain unclear. This study explored the prognostic significance of LCP2 in LUAD patients.
methodsLCP2 expression in LUAD tissues was analyzed using data from The Cancer Genome Atlas and Genotype-Tissue Expression databases. Western blotting was employed to detect LCP2 expression in LUAD. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were performed to explore signaling pathways mediated by LCP2 co-regulatory genes. Immunohistochemistry was used to examine levels of LCP2 and programmed death ligand 1 (PD-L1) in 68 LUAD patients. Associations between LCP2 expression and clinicopathological features, prognoses, and PD-L1 levels among the LUAD in-patients were analyzed.
resultsAmong the 68 LUAD in-patients, LCP2 expression was correlated with clinical stage and lymph node metastasis. LUAD patients with high LCP2 expression were associated with increased overall survival. LCP2 expression may be associated with an enrichment of several immune functions. Moreover, our immunohistochemistry results demonstrated that LCP2 expression was positively correlated with PD-L1 expression in LUAD tissues.
conclusionsIn the study, LCP2 was found to be a favorable prognostic biomarker in LUAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.